EvoNexus
Adam Watson, PhD, is a biotechnology entrepreneur and scientist, currently serving as Co-Founder and CEO of MeCo Diagnostics, a venture-backed startup focused on developing predictive biomarker tests for antifibrotic drug repurposing in early-stage breast and prostate cancer patients. In addition to this role, Adam holds positions as an Entrepreneur in Residence at EvoNexus and as a Grants Reviewer for Genome Canada. Adam's prior experience includes roles as a Scientist at Lynx Biosciences, Inc., and Associate Scientist at Hawkeye Spectral Imaging LLC, along with a postdoctoral fellowship at the University of Arizona College of Medicine, where a multivariate prognostic biomarker for breast cancer was clinically validated. Adam Watson earned a PhD in Cancer Biology from the University of Arizona and a B.Sc. in Microbiology from the University of Victoria.
EvoNexus
EvoNexus is a technology incubator for Southern California's startup and entrepreneurial community with locations in San Diego and Irvine. EvoNexus empowers motivated entrepreneurs to turn their transformative ideas into fundable, commercially viable companies and leverages community resources to provide what entrepreneurs need to besuccessful.